Synopsis: Eplerenone, a potassium-sparing diuretic similar to spironolactone, selectively blocks aldosterone to lower blood pressure. However, its safety profile is improved over spironolactone because of reduced progesterone and androgen-receptor effects. It is labeled for treatment of hypertension, either alone or in combination. It has been studied in postmyocardial infarction (MI) patients with left ventricular dysfunction.
|Approximate monthly cost*
|1 50-mg tablet, orally daily
|25-mg, 50-mg, and 100-mg tablets
Safety: As with spironolactone, hyperkalemia can occur, with a prevalence ranging from 2.6 percent in patients with normal renal function to more than 10 percent in patients with mild renal dysfunction (creatinine clearance [CrCl] less than 70 mL per min).1 Hyperkalemia occurs more frequently in persons with diabetes, particularly when eplerenone is given with angiotensin-converting enzyme (ACE) inhibitors; 38 percent receiving this combination had hyperkalemia.1 Eplerenone is category B in pregnancy. It is contraindicated in patients with hyperkalemia (serum potassium more than 5.5 mEq per L), type 2 diabetes with microalbuminuria, or moderate renal dysfunction (CrCl less than 50 mL per min [0.83 mL per sec], serum creatinine more than 2.0 mg per dL (150 μmol per L) in men or more than 1.8 mg per dL (140 μmol per L) in women, and in those taking potassium supplements or with other potassium-sparing diuretics (amiloride, triamterene, or spironolactone).1 Eplerenone serum levels are increased when taken with detoconazole, erythromycin, saquinavir, verapamil, fluconazole, and grapefruit juice.1
Effectiveness: In patients with hypertension, eplerenone (50 to 200 mg daily) will lower blood pressure an average of 6 to 24 mm Hg systolic and 4 to 14 mm Hg diastolic.1,4–6 In comparative trials, eplerenone produced anti-hypertensive effects similar to those of enalapril, losartan, amlodipine, and spironolactone. It has lowered blood pressure particularly well in low-renin, salt-sensitive patients (mean diastolic reduction of 12.8 mm Hg, P <.001).5 There are no data from trials that examine the effect of eplerenone on mortality or morbidity in the treatment of hypertension.
There are no data on the effect of eplerenone in patients with heart failure except in post-MI patients who have an ejection fraction of less than 35 percent.3 In these patients, who also were receiving conventional therapy, the one-year mortality rate was lower in patients treated with eplerenone compared with placebo (11.8 versus 13.6 percent). Over 1.25 years, this difference translates into one fewer death for every 43 patients (range, 24 to 142) receiving eplerenone in conjunction with standard treatment. In addition, eplerenone reduced the combined outcome of deaths from cardiovascular causes or hospitalizations for cardiovascular events (26.7 versus 30 percent; number needed to treat: 30, 95 percent CI, 16 to 67). This effect was largely the result of a 21 percent relative reduction in sudden death among patients taking eplerenone.3
Price: A one-month supply of eplerenone will cost patients $113. This price is significantly higher than the cost of spironolactone, which is approximately $30 per month.
Simplicity: Inspra is supplied as 25-mg, 50-mg, or 100-mg tablets. The recommended starting dosage for antihypertensive treatment is one 50-mg tablet daily. Monitoring recommendations include determination of potassium concentrations every two weeks for the initial one to two months and then monthly thereafter, which would add considerably to the cost and complexity of therapy.1
Bottom line: Compared with other commonly used antihypertensive medications, eplerenone is effective in lowering blood pressure when used alone or as add-on therapy. However, mortality benefits related to antihypertensive treatment have not yet been shown, so it should not be considered a first-line treatment for hypertension. Mortality benefits have been observed with eplerenone in patients with left ventricular dysfunction who were receiving appropriate pharmacotherapy following an MI. It is unclear whether the advantages gained by an improved eplerenone side effect profile counter the cost or proven efficacy associated with appropriately dosed and monitored spironolactone therapy in patients with heart failure.